Dr. Vijay Balasubramanian
Medical Director at VALDI Inc.
Board-Certified Pulmonologist | Clinical Professor | Advocate for Pulmonary Hypertension Care
Dr. Vijay Balasubramanian, MD, MRCP (UK), FCCP, is a Board-Certified Pulmonologist specializing in advanced lung diseases, particularly pulmonary hypertension. His clinical excellence, groundbreaking research, and leadership in medical education have earned him national recognition.
CURRENT ROLES & LEADERSHIP
-
Clinical Professor of Medicine at CHSU, Clovis, CA
-
Ex Officio Section Chair of Pulmonary Vascular Network, American College of Chest Physicians
-
Board Member of Team Phenomenal Hope
-
Co-Chair of Access to Care Task Force, Innovative Drug Development Initiative, Pulmonary Vascular Research Institute (PVRI)
-
Editorial Board Member for Chest Pulmonary Journal, Chest Physician, and Advances in Pulmonary Hypertension (PHA)
Dr. Bala is also the Medical Director at VALDI Inc, where he directs innovative strategies to advance pulmonary care and research.
CAREER HIGHLIGHTS & CONTRIBUTIONS
Dr. Bala is recognized for establishing the Central Valley’s first accredited Pulmonary Hypertension Program at UCSF Fresno. His work set new benchmarks in the region’s pulmonary care. He is a nationally sought-after speaker, presenting his expertise on pulmonary diseases at medical conferences across the U.S.
In addition to his clinical and academic roles, Dr. Bala has taken on prominent leadership positions in professional organizations, such as the American College of Chest Physicians and the Pulmonary Vascular Research Institute.
Patient Advocacy and Community Impact:
Dr. Bala co-founded the Central Valley Pulmonary Hypertension Support Group, providing vital education and support to patients and families affected by pulmonary hypertension. His patient-centered approach emphasizes compassion, community, and holistic care.
As a leader in pulmonary medicine, Dr. Bala continues to innovate and advocate for patient access to care, with a vision focused on excellence and improvement in pulmonary health outcomes.